Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Inflammatory Carcinoma: early-phase trial registry
1 of 4 indexed Breast Inflammatory Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Breast Inflammatory Carcinoma: 4 US clinical trials tracked, 1 recruiting.
Breast Inflammatory Carcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition breast-inflammatory-carcinoma
OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Breast Inflammatory Carcinoma lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Inflammatory Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Inflammatory Carcinoma is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
M.D. Anderson Cancer Center
NCT03941756
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
National Cancer Institute (NCI)
NCT03598257
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Academic and Community Cancer Research United
NCT03012100
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
M.D. Anderson Cancer Center
NCT02971748
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Inflammatory Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Inflammatory Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Inflammatory Carcinoma page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Breast Inflammatory Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Breast Inflammatory Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Inflammatory Carcinoma condition card totals 4 registered trials; most-linked intervention Multi-epitope Folate Receptor Alpha Peptide Vaccine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.